Accardi Mario Alberto
Chief Executive Officer
Accardi Mario Alberto has filed 9 SEC Form 4 filings (15 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Jun 24, 2026.
On the most recent filing, Accardi Mario Alberto is listed as President, Orexin Program at Centessa Pharmaceuticals plc. Inside the rolling window, Accardi Mario Alberto reported no open-market purchases and 3 open-market sales totaling $788K in CNTA. The largest disclosed transaction in the window is a sale of 10,000 CNTA shares on Dec 8, 2025, worth $300K.
Companies traded
Other insiders at CNTA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$788K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Accardi Mario Alberto made?
Accardi Mario Alberto has filed 9 SEC Form 4 filings (15 transaction rows) across 1 company since 2025.
Which companies does Accardi Mario Alberto trade?
Accardi Mario Alberto has filed SEC Form 4 disclosures for 1 company, including CNTA.
When was Accardi Mario Alberto's most recent SEC Form 4 filing?
Accardi Mario Alberto's most recent SEC Form 4 filing on Tracefour is dated Jun 24, 2026.
What is Accardi Mario Alberto's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Accardi Mario Alberto is listed as Chief Executive Officer.
What is Accardi Mario Alberto's total buy and sell value in the current window?
Inside the rolling retention window, Accardi Mario Alberto bought $0 and sold $788K based on SEC Form 4 filings.
What was Accardi Mario Alberto's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,000 CNTA shares on 2025-12-08, worth $300K, per SEC Form 4 filings.